Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease (Q33911859)

30 July 2017

title

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease (English)

1 reference

30 July 2017

0 references

1

Martin Farlow

1 reference

30 July 2017

Felix Veloso

2

1 reference

30 July 2017

Margaret Moline

3

1 reference

30 July 2017

Jane Yardley

4

1 reference

30 July 2017

Elimor Brand-Schieber

5

1 reference

30 July 2017

Francesco Bibbiani

6

1 reference

30 July 2017

Heng Zou

7

1 reference

30 July 2017

Timothy Hsu

8

1 reference

30 July 2017

Andrew Satlin

9

1 reference

30 July 2017

publication date

25 May 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

page(s)

57

1 reference

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

5 July 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2377-11-57

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2377-11-57

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2377-11-57

Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2377-11-57

21 January 2018

Identifiers

DOI

10.1186/1471-2377-11-57

1 reference

Dimensions Publication ID

30 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-11-57

9 September 2019

1 reference

30 July 2017

1 reference